Immunovia AB Stock London S.E.

Equities

0G8X

SE0006091997

Advanced Medical Equipment & Technology

Market Closed - London S.E. 06:13:42 2024-03-21 am EDT 5-day change 1st Jan Change
1.4 SEK -96.26% Intraday chart for Immunovia AB -.--% -22.82%
Sales 2021 844K 77.44K Sales 2022 1.14M 105K Capitalization 595M 54.61M
Net income 2021 -156M -14.31M Net income 2022 -168M -15.42M EV / Sales 2021 1,710 x
Net cash position 2021 254M 23.32M Net cash position 2022 68.47M 6.28M EV / Sales 2022 460 x
P/E ratio 2021
-10.9 x
P/E ratio 2022
-3.54 x
Employees 11
Yield 2021 *
-
Yield 2022
-
Free-Float 75.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day-96.26%
3 months-27.79%
6 months+41.56%
Current year-22.82%
More quotes
Current year
1.40
Extreme 1.4
2.26
1 year
0.99
Extreme 0.985
4.50
3 years
0.99
Extreme 0.985
139.14
5 years
0.99
Extreme 0.985
292.00
10 years
0.99
Extreme 0.985
292.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 62 22-03-31
Chief Operating Officer 61 23-02-28
Members of the board TitleAgeSince
Director/Board Member 70 16-12-08
Chairman 67 19-12-31
Director/Board Member - 23-05-21
More insiders
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
More about the company